Dubai, UAE – Fundayo’s pharmaceutical product “Orfurglebrone” highlights an innovative oral treatment to reduce weight gain (obesity). Which was recently announced as approved by the Emirates Pharmaceutical Foundation, as one of the most prominent innovations in this field. It offers a different approach to weight management, based on comfort and ease of use, unlike many traditional treatments.
This new oral medication, launched by the medical company (Lilly) “Laila”, comes in the form of a tablet used once a day without complex restrictions related to food or drink time. It provides an additional option for people suffering from obesity, supporting disease management methods.
Roberta Marinelli, President and General Manager of the Middle East, Turkey and Africa at Lilly, explained that Orfurglebron showed remarkable results during clinical trials. It represented a noticeable weight loss when used in conjunction with lifestyle modification guidelines.
Participants who received the highest dose recorded an average weight loss of 12.4%. Noting that Orfurgliprone is expected to be available to eligible patients in the UAE starting next May.
She added: “In a fast-paced world, success in health care is no longer just about results, but how easily they can be integrated into daily life”. Hence, a new generation of treatments is emerging that not only deliver effectiveness, but also completely redefine the experience to become simpler and more flexible.”
She stated that clinical studies have shown that using the treatment in conjunction with lifestyle improvements can achieve significant weight loss.
